The global Radionuclide-conjugated Drugs market was valued at US$ million in 2025 and is anticipated to reach US$ million by 2032, at a CAGR of %from 2026 to 2032.

Radioimmunotherapy (RIT) is a type of targeted cancer therapy that combines the specificity of monoclonal antibodies with the destructive power of radiation. The treatment involves attaching radioactive isotopes to monoclonal antibodies, which are specialized proteins that can recognize and bind to specific antigens found on the surface of cancer cells.

The North American market for Radionuclide-conjugated Drugs is projected to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.

The Asia-Pacific market for Radionuclide-conjugated Drugs is projected to rise from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.

The global market for Radionuclide-conjugated Drugs in Solid Tumor is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 to 2032.

Major global companies of Radionuclide-conjugated Drugs include Bayer, Novartis, Lantheus, Aurobindo Pharma, Mundipharma, China Isotope & Radiation, Curium Pharmaceuticals, Gilead Sciences, Clarity Pharmaceuticals, Curasight, etc. In 2025, the world's top three vendors accounted for approximately % of revenue.

This report delivers a comprehensive overview of the global Radionuclide-conjugated Drugs market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Radionuclide-conjugated Drugs. The Radionuclide-conjugated Drugs market size, estimates, and forecasts are provided in terms of revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.

The report segments the global Radionuclide-conjugated Drugs market comprehensively. Regional market sizes by Type, by Application, , and by player are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.

This report will assist Radionuclide-conjugated Drugs manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

Market Segmentation

Scope of Radionuclide-conjugated Drugs Market Report

Report Metric	Details
Report Name	Radionuclide-conjugated Drugs Market
Segment by Type	Beta-emitting Targeted Alpha Therapy
Segment by Application	Solid Tumor Non Hodgkin Lymphoma
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Bayer, Novartis, Lantheus, Aurobindo Pharma, Mundipharma, China Isotope & Radiation, Curium Pharmaceuticals, Gilead Sciences, Clarity Pharmaceuticals, Curasight, Nordic Nanovector, Philogen, RadioMedix, Telix Pharmaceuticals, Orano Med, Actinium Pharmaceuticals, Y-mAbs Therapeutics, Fusion Pharmaceuticals
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Summarizes global and regional market size and outlines market dynamics and recent developments, including key drivers, restraints, challenges and risks for industry participants, and relevant policy analysis.
Chapter 3: Provides a detailed view of the competitive landscape for Radionuclide-conjugated Drugs companies, covering revenue share, development plans, and mergers and acquisitions.
Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify blue-ocean opportunities.
Chapter 5: Analyzes segments by Application, detailing the size and growth potential of each downstream segment to help readers identify blue-ocean opportunities.
Chapter 6–10: Regional deep dives (North America, Europe, Asia Pacific, Latin America, Middle East & Africa) broken down by country. Each chapter quantifies market size and growth potential by region and key countries, and outlines market development, outlook, addressable space, and capacity.
Chapter 11: Profiles key players, presenting essential information on leading companies, including product/ service offerings, revenue, gross margin, product introductions/portfolios, recent developments, etc.
Chapter 12: Key findings and conclusions of the report.

FAQ for this report

Who are the main players in the Radionuclide-conjugated Drugs Market report?

Ans: The main players in the Radionuclide-conjugated Drugs Market are Bayer, Novartis, Lantheus, Aurobindo Pharma, Mundipharma, China Isotope & Radiation, Curium Pharmaceuticals, Gilead Sciences, Clarity Pharmaceuticals, Curasight, Nordic Nanovector, Philogen, RadioMedix, Telix Pharmaceuticals, Orano Med, Actinium Pharmaceuticals, Y-mAbs Therapeutics, Fusion Pharmaceuticals

What are the Application segmentation covered in the Radionuclide-conjugated Drugs Market report?

Ans: The Applications covered in the Radionuclide-conjugated Drugs Market report are Solid Tumor, Non Hodgkin Lymphoma

What are the Type segmentation covered in the Radionuclide-conjugated Drugs Market report?

Ans: The Types covered in the Radionuclide-conjugated Drugs Market report are Beta-emitting, Targeted Alpha Therapy

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Radionuclide-conjugated Drugs Market Size Growth Rate by Type: 2021 vs 2025 vs 2032

1.2.2 Beta-emitting

1.2.3 Targeted Alpha Therapy

1.3 Market by Application

1.3.1 Global Radionuclide-conjugated Drugs Market Growth by Application: 2021 vs 2025 vs 2032

1.3.2 Solid Tumor

1.3.3 Non Hodgkin Lymphoma

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Global Growth Trends

2.1 Global Radionuclide-conjugated Drugs Market Perspective (2021–2032)

2.2 Global Radionuclide-conjugated Drugs Growth Trends by Region

2.2.1 Global Radionuclide-conjugated Drugs Market Size by Region: 2021 vs 2025 vs 2032

2.2.2 Radionuclide-conjugated Drugs Historic Market Size by Region (2021–2026)

2.2.3 Radionuclide-conjugated Drugs Forecasted Market Size by Region (2027–2032)

2.3 Radionuclide-conjugated Drugs Market Dynamics

2.3.1 Radionuclide-conjugated Drugs Industry Trends

2.3.2 Radionuclide-conjugated Drugs Market Drivers

2.3.3 Radionuclide-conjugated Drugs Market Challenges

2.3.4 Radionuclide-conjugated Drugs Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Radionuclide-conjugated Drugs Players by Revenue

3.1.1 Global Top Radionuclide-conjugated Drugs Players by Revenue (2021–2026)

3.1.2 Global Radionuclide-conjugated Drugs Revenue Market Share by Players (2021–2026)

3.2 Global Top Radionuclide-conjugated Drugs Players Market Share by Company Tier (Tier 1, Tier 2, Tier 3)

3.3 Global Key Players Ranking by Radionuclide-conjugated Drugs Revenue

3.4 Global Radionuclide-conjugated Drugs Market Concentration Ratio

3.4.1 Global Radionuclide-conjugated Drugs Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Radionuclide-conjugated Drugs Revenue in 2025

3.5 Global Key Players of Radionuclide-conjugated Drugs Head Offices and Areas Served

3.6 Global Key Players of Radionuclide-conjugated Drugs, Products and Applications

3.7 Global Key Players of Radionuclide-conjugated Drugs, Date of General Availability (GA)

3.8 Mergers and Acquisitions, Expansion Plans

4 Radionuclide-conjugated Drugs Breakdown Data by Type

4.1 Global Radionuclide-conjugated Drugs Historic Market Size by Type (2021–2026)

4.2 Global Radionuclide-conjugated Drugs Forecasted Market Size by Type (2027–2032)

5 Radionuclide-conjugated Drugs Breakdown Data by Application

5.1 Global Radionuclide-conjugated Drugs Historic Market Size by Application (2021–2026)

5.2 Global Radionuclide-conjugated Drugs Forecasted Market Size by Application (2027–2032)

6 North America

6.1 North America Radionuclide-conjugated Drugs Market Size (2021–2032)

6.2 North America Radionuclide-conjugated Drugs Market Growth Rate by Country: 2021 vs 2025 vs 2032

6.3 North America Radionuclide-conjugated Drugs Market Size by Country (2021–2026)

6.4 North America Radionuclide-conjugated Drugs Market Size by Country (2027–2032)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Radionuclide-conjugated Drugs Market Size (2021–2032)

7.2 Europe Radionuclide-conjugated Drugs Market Growth Rate by Country: 2021 vs 2025 vs 2032

7.3 Europe Radionuclide-conjugated Drugs Market Size by Country (2021–2026)

7.4 Europe Radionuclide-conjugated Drugs Market Size by Country (2027–2032)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Ireland

8 Asia-Pacific

8.1 Asia-Pacific Radionuclide-conjugated Drugs Market Size (2021–2032)

8.2 Asia-Pacific Radionuclide-conjugated Drugs Market Growth Rate by Region: 2021 vs 2025 vs 2032

8.3 Asia-Pacific Radionuclide-conjugated Drugs Market Size by Region (2021–2026)

8.4 Asia-Pacific Radionuclide-conjugated Drugs Market Size by Region (2027–2032)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia & New Zealand

9 Latin America

9.1 Latin America Radionuclide-conjugated Drugs Market Size (2021–2032)

9.2 Latin America Radionuclide-conjugated Drugs Market Growth Rate by Country: 2021 vs 2025 vs 2032

9.3 Latin America Radionuclide-conjugated Drugs Market Size by Country (2021–2026)

9.4 Latin America Radionuclide-conjugated Drugs Market Size by Country (2027–2032)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Radionuclide-conjugated Drugs Market Size (2021–2032)

10.2 Middle East & Africa Radionuclide-conjugated Drugs Market Growth Rate by Country: 2021 vs 2025 vs 2032

10.3 Middle East & Africa Radionuclide-conjugated Drugs Market Size by Country (2021–2026)

10.4 Middle East & Africa Radionuclide-conjugated Drugs Market Size by Country (2027–2032)

10.5 Israel

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Bayer

11.1.1 Bayer Company Details

11.1.2 Bayer Business Overview

11.1.3 Bayer Radionuclide-conjugated Drugs Introduction

11.1.4 Bayer Revenue in Radionuclide-conjugated Drugs Business (2021–2026)

11.1.5 Bayer Recent Development

11.2 Novartis

11.2.1 Novartis Company Details

11.2.2 Novartis Business Overview

11.2.3 Novartis Radionuclide-conjugated Drugs Introduction

11.2.4 Novartis Revenue in Radionuclide-conjugated Drugs Business (2021–2026)

11.2.5 Novartis Recent Development

11.3 Lantheus

11.3.1 Lantheus Company Details

11.3.2 Lantheus Business Overview

11.3.3 Lantheus Radionuclide-conjugated Drugs Introduction

11.3.4 Lantheus Revenue in Radionuclide-conjugated Drugs Business (2021–2026)

11.3.5 Lantheus Recent Development

11.4 Aurobindo Pharma

11.4.1 Aurobindo Pharma Company Details

11.4.2 Aurobindo Pharma Business Overview

11.4.3 Aurobindo Pharma Radionuclide-conjugated Drugs Introduction

11.4.4 Aurobindo Pharma Revenue in Radionuclide-conjugated Drugs Business (2021–2026)

11.4.5 Aurobindo Pharma Recent Development

11.5 Mundipharma

11.5.1 Mundipharma Company Details

11.5.2 Mundipharma Business Overview

11.5.3 Mundipharma Radionuclide-conjugated Drugs Introduction

11.5.4 Mundipharma Revenue in Radionuclide-conjugated Drugs Business (2021–2026)

11.5.5 Mundipharma Recent Development

11.6 China Isotope & Radiation

11.6.1 China Isotope & Radiation Company Details

11.6.2 China Isotope & Radiation Business Overview

11.6.3 China Isotope & Radiation Radionuclide-conjugated Drugs Introduction

11.6.4 China Isotope & Radiation Revenue in Radionuclide-conjugated Drugs Business (2021–2026)

11.6.5 China Isotope & Radiation Recent Development

11.7 Curium Pharmaceuticals

11.7.1 Curium Pharmaceuticals Company Details

11.7.2 Curium Pharmaceuticals Business Overview

11.7.3 Curium Pharmaceuticals Radionuclide-conjugated Drugs Introduction

11.7.4 Curium Pharmaceuticals Revenue in Radionuclide-conjugated Drugs Business (2021–2026)

11.7.5 Curium Pharmaceuticals Recent Development

11.8 Gilead Sciences

11.8.1 Gilead Sciences Company Details

11.8.2 Gilead Sciences Business Overview

11.8.3 Gilead Sciences Radionuclide-conjugated Drugs Introduction

11.8.4 Gilead Sciences Revenue in Radionuclide-conjugated Drugs Business (2021–2026)

11.8.5 Gilead Sciences Recent Development

11.9 Clarity Pharmaceuticals

11.9.1 Clarity Pharmaceuticals Company Details

11.9.2 Clarity Pharmaceuticals Business Overview

11.9.3 Clarity Pharmaceuticals Radionuclide-conjugated Drugs Introduction

11.9.4 Clarity Pharmaceuticals Revenue in Radionuclide-conjugated Drugs Business (2021–2026)

11.9.5 Clarity Pharmaceuticals Recent Development

11.10 Curasight

11.10.1 Curasight Company Details

11.10.2 Curasight Business Overview

11.10.3 Curasight Radionuclide-conjugated Drugs Introduction

11.10.4 Curasight Revenue in Radionuclide-conjugated Drugs Business (2021–2026)

11.10.5 Curasight Recent Development

11.11 Nordic Nanovector

11.11.1 Nordic Nanovector Company Details

11.11.2 Nordic Nanovector Business Overview

11.11.3 Nordic Nanovector Radionuclide-conjugated Drugs Introduction

11.11.4 Nordic Nanovector Revenue in Radionuclide-conjugated Drugs Business (2021–2026)

11.11.5 Nordic Nanovector Recent Development

11.12 Philogen

11.12.1 Philogen Company Details

11.12.2 Philogen Business Overview

11.12.3 Philogen Radionuclide-conjugated Drugs Introduction

11.12.4 Philogen Revenue in Radionuclide-conjugated Drugs Business (2021–2026)

11.12.5 Philogen Recent Development

11.13 RadioMedix

11.13.1 RadioMedix Company Details

11.13.2 RadioMedix Business Overview

11.13.3 RadioMedix Radionuclide-conjugated Drugs Introduction

11.13.4 RadioMedix Revenue in Radionuclide-conjugated Drugs Business (2021–2026)

11.13.5 RadioMedix Recent Development

11.14 Telix Pharmaceuticals

11.14.1 Telix Pharmaceuticals Company Details

11.14.2 Telix Pharmaceuticals Business Overview

11.14.3 Telix Pharmaceuticals Radionuclide-conjugated Drugs Introduction

11.14.4 Telix Pharmaceuticals Revenue in Radionuclide-conjugated Drugs Business (2021–2026)

11.14.5 Telix Pharmaceuticals Recent Development

11.15 Orano Med

11.15.1 Orano Med Company Details

11.15.2 Orano Med Business Overview

11.15.3 Orano Med Radionuclide-conjugated Drugs Introduction

11.15.4 Orano Med Revenue in Radionuclide-conjugated Drugs Business (2021–2026)

11.15.5 Orano Med Recent Development

11.16 Actinium Pharmaceuticals

11.16.1 Actinium Pharmaceuticals Company Details

11.16.2 Actinium Pharmaceuticals Business Overview

11.16.3 Actinium Pharmaceuticals Radionuclide-conjugated Drugs Introduction

11.16.4 Actinium Pharmaceuticals Revenue in Radionuclide-conjugated Drugs Business (2021–2026)

11.16.5 Actinium Pharmaceuticals Recent Development

11.17 Y-mAbs Therapeutics

11.17.1 Y-mAbs Therapeutics Company Details

11.17.2 Y-mAbs Therapeutics Business Overview

11.17.3 Y-mAbs Therapeutics Radionuclide-conjugated Drugs Introduction

11.17.4 Y-mAbs Therapeutics Revenue in Radionuclide-conjugated Drugs Business (2021–2026)

11.17.5 Y-mAbs Therapeutics Recent Development

11.18 Fusion Pharmaceuticals

11.18.1 Fusion Pharmaceuticals Company Details

11.18.2 Fusion Pharmaceuticals Business Overview

11.18.3 Fusion Pharmaceuticals Radionuclide-conjugated Drugs Introduction

11.18.4 Fusion Pharmaceuticals Revenue in Radionuclide-conjugated Drugs Business (2021–2026)

11.18.5 Fusion Pharmaceuticals Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.1.1 Research Programs/Design

13.1.1.2 Market Size Estimation

13.1.1.3 Market Breakdown and Data Triangulation

13.1.2 Data Source

13.1.2.1 Secondary Sources

13.1.2.2 Primary Sources

13.2 Author Details

13.3 Disclaimer

FEATURED COMPANIES

China Isotope & Radiation

Curium Pharmaceuticals

Gilead Sciences

Clarity Pharmaceuticals

Telix Pharmaceuticals

Orano Med

Actinium Pharmaceuticals

Y-mAbs Therapeutics

Fusion Pharmaceuticals

List of Tables

Table 1. Global Radionuclide-conjugated Drugs Market Size Growth Rate by Type (US$ Million): 2021 vs 2025 vs 2032

Table 2. Key Players of Beta-emitting

Table 3. Key Players of Targeted Alpha Therapy

Table 4. Global Radionuclide-conjugated Drugs Market Size Growth by Application (US$ Million): 2021 vs 2025 vs 2032

Table 5. Global Radionuclide-conjugated Drugs Market Size by Region (US$ Million): 2021 vs 2025 vs 2032

Table 6. Global Radionuclide-conjugated Drugs Market Size by Region (US$ Million), 2021–2026

Table 7. Global Radionuclide-conjugated Drugs Market Share by Region (2021–2026)

Table 8. Global Radionuclide-conjugated Drugs Forecasted Market Size by Region (US$ Million), 2027–2032

Table 9. Global Radionuclide-conjugated Drugs Market Share by Region (2027–2032)

Table 10. Radionuclide-conjugated Drugs Market Trends

Table 11. Radionuclide-conjugated Drugs Market Drivers

Table 12. Radionuclide-conjugated Drugs Market Challenges

Table 13. Radionuclide-conjugated Drugs Market Restraints

Table 14. Global Radionuclide-conjugated Drugs Revenue by Players (US$ Million), 2021–2026

Table 15. Global Radionuclide-conjugated Drugs Market Share by Players (2021–2026)

Table 16. Global Top Radionuclide-conjugated Drugs Players by Tier (Tier 1, Tier 2, and Tier 3), based on Radionuclide-conjugated Drugs Revenue, 2025

Table 17. Ranking of Global Top Radionuclide-conjugated Drugs Companies by Revenue (US$ Million) in 2025

Table 18. Global 5 Largest Players Market Share by Radionuclide-conjugated Drugs Revenue (CR5 and HHI), 2021–2026

Table 19. Global Key Players of Radionuclide-conjugated Drugs, Headquarters and Area Served

Table 20. Global Key Players of Radionuclide-conjugated Drugs, Products and Applications

Table 21. Global Key Players of Radionuclide-conjugated Drugs, Date of General Availability (GA)

Table 22. Mergers and Acquisitions, Expansion Plans

Table 23. Global Radionuclide-conjugated Drugs Market Size by Type (US$ Million), 2021–2026

Table 24. Global Radionuclide-conjugated Drugs Revenue Market Share by Type (2021–2026)

Table 25. Global Radionuclide-conjugated Drugs Forecasted Market Size by Type (US$ Million), 2027–2032

Table 26. Global Radionuclide-conjugated Drugs Revenue Market Share by Type (2027–2032)

Table 27. Global Radionuclide-conjugated Drugs Market Size by Application (US$ Million), 2021–2026

Table 28. Global Radionuclide-conjugated Drugs Revenue Market Share by Application (2021–2026)

Table 29. Global Radionuclide-conjugated Drugs Forecasted Market Size by Application (US$ Million), 2027–2032

Table 30. Global Radionuclide-conjugated Drugs Revenue Market Share by Application (2027–2032)

Table 31. North America Radionuclide-conjugated Drugs Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032

Table 32. North America Radionuclide-conjugated Drugs Market Size by Country (US$ Million), 2021–2026

Table 33. North America Radionuclide-conjugated Drugs Market Size by Country (US$ Million), 2027–2032

Table 34. Europe Radionuclide-conjugated Drugs Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032

Table 35. Europe Radionuclide-conjugated Drugs Market Size by Country (US$ Million), 2021–2026

Table 36. Europe Radionuclide-conjugated Drugs Market Size by Country (US$ Million), 2027–2032

Table 37. Asia-Pacific Radionuclide-conjugated Drugs Market Size Growth Rate by Region (US$ Million): 2021 vs 2025 vs 2032

Table 38. Asia-Pacific Radionuclide-conjugated Drugs Market Size by Region (US$ Million), 2021–2026

Table 39. Asia-Pacific Radionuclide-conjugated Drugs Market Size by Region (US$ Million), 2027–2032

Table 40. Latin America Radionuclide-conjugated Drugs Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032

Table 41. Latin America Radionuclide-conjugated Drugs Market Size by Country (US$ Million), 2021–2026

Table 42. Latin America Radionuclide-conjugated Drugs Market Size by Country (US$ Million), 2027–2032

Table 43. Middle East & Africa Radionuclide-conjugated Drugs Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032

Table 44. Middle East & Africa Radionuclide-conjugated Drugs Market Size by Country (US$ Million), 2021–2026

Table 45. Middle East & Africa Radionuclide-conjugated Drugs Market Size by Country (US$ Million), 2027–2032

Table 46. Bayer Company Details

Table 47. Bayer Business Overview

Table 48. Bayer Radionuclide-conjugated Drugs Product

Table 49. Bayer Revenue in Radionuclide-conjugated Drugs Business (US$ Million), 2021–2026

Table 50. Bayer Recent Development

Table 51. Novartis Company Details

Table 52. Novartis Business Overview

Table 53. Novartis Radionuclide-conjugated Drugs Product

Table 54. Novartis Revenue in Radionuclide-conjugated Drugs Business (US$ Million), 2021–2026

Table 55. Novartis Recent Development

Table 56. Lantheus Company Details

Table 57. Lantheus Business Overview

Table 58. Lantheus Radionuclide-conjugated Drugs Product

Table 59. Lantheus Revenue in Radionuclide-conjugated Drugs Business (US$ Million), 2021–2026

Table 60. Lantheus Recent Development

Table 61. Aurobindo Pharma Company Details

Table 62. Aurobindo Pharma Business Overview

Table 63. Aurobindo Pharma Radionuclide-conjugated Drugs Product

Table 64. Aurobindo Pharma Revenue in Radionuclide-conjugated Drugs Business (US$ Million), 2021–2026

Table 65. Aurobindo Pharma Recent Development

Table 66. Mundipharma Company Details

Table 67. Mundipharma Business Overview

Table 68. Mundipharma Radionuclide-conjugated Drugs Product

Table 69. Mundipharma Revenue in Radionuclide-conjugated Drugs Business (US$ Million), 2021–2026

Table 70. Mundipharma Recent Development

Table 71. China Isotope & Radiation Company Details

Table 72. China Isotope & Radiation Business Overview

Table 73. China Isotope & Radiation Radionuclide-conjugated Drugs Product

Table 74. China Isotope & Radiation Revenue in Radionuclide-conjugated Drugs Business (US$ Million), 2021–2026

Table 75. China Isotope & Radiation Recent Development

Table 76. Curium Pharmaceuticals Company Details

Table 77. Curium Pharmaceuticals Business Overview

Table 78. Curium Pharmaceuticals Radionuclide-conjugated Drugs Product

Table 79. Curium Pharmaceuticals Revenue in Radionuclide-conjugated Drugs Business (US$ Million), 2021–2026

Table 80. Curium Pharmaceuticals Recent Development

Table 81. Gilead Sciences Company Details

Table 82. Gilead Sciences Business Overview

Table 83. Gilead Sciences Radionuclide-conjugated Drugs Product

Table 84. Gilead Sciences Revenue in Radionuclide-conjugated Drugs Business (US$ Million), 2021–2026

Table 85. Gilead Sciences Recent Development

Table 86. Clarity Pharmaceuticals Company Details

Table 87. Clarity Pharmaceuticals Business Overview

Table 88. Clarity Pharmaceuticals Radionuclide-conjugated Drugs Product

Table 89. Clarity Pharmaceuticals Revenue in Radionuclide-conjugated Drugs Business (US$ Million), 2021–2026

Table 90. Clarity Pharmaceuticals Recent Development

Table 91. Curasight Company Details

Table 92. Curasight Business Overview

Table 93. Curasight Radionuclide-conjugated Drugs Product

Table 94. Curasight Revenue in Radionuclide-conjugated Drugs Business (US$ Million), 2021–2026

Table 95. Curasight Recent Development

Table 96. Nordic Nanovector Company Details

Table 97. Nordic Nanovector Business Overview

Table 98. Nordic Nanovector Radionuclide-conjugated Drugs Product

Table 99. Nordic Nanovector Revenue in Radionuclide-conjugated Drugs Business (US$ Million), 2021–2026

Table 100. Nordic Nanovector Recent Development

Table 101. Philogen Company Details

Table 102. Philogen Business Overview

Table 103. Philogen Radionuclide-conjugated Drugs Product

Table 104. Philogen Revenue in Radionuclide-conjugated Drugs Business (US$ Million), 2021–2026

Table 105. Philogen Recent Development

Table 106. RadioMedix Company Details

Table 107. RadioMedix Business Overview

Table 108. RadioMedix Radionuclide-conjugated Drugs Product

Table 109. RadioMedix Revenue in Radionuclide-conjugated Drugs Business (US$ Million), 2021–2026

Table 110. RadioMedix Recent Development

Table 111. Telix Pharmaceuticals Company Details

Table 112. Telix Pharmaceuticals Business Overview

Table 113. Telix Pharmaceuticals Radionuclide-conjugated Drugs Product

Table 114. Telix Pharmaceuticals Revenue in Radionuclide-conjugated Drugs Business (US$ Million), 2021–2026

Table 115. Telix Pharmaceuticals Recent Development

Table 116. Orano Med Company Details

Table 117. Orano Med Business Overview

Table 118. Orano Med Radionuclide-conjugated Drugs Product

Table 119. Orano Med Revenue in Radionuclide-conjugated Drugs Business (US$ Million), 2021–2026

Table 120. Orano Med Recent Development

Table 121. Actinium Pharmaceuticals Company Details

Table 122. Actinium Pharmaceuticals Business Overview

Table 123. Actinium Pharmaceuticals Radionuclide-conjugated Drugs Product

Table 124. Actinium Pharmaceuticals Revenue in Radionuclide-conjugated Drugs Business (US$ Million), 2021–2026

Table 125. Actinium Pharmaceuticals Recent Development

Table 126. Y-mAbs Therapeutics Company Details

Table 127. Y-mAbs Therapeutics Business Overview

Table 128. Y-mAbs Therapeutics Radionuclide-conjugated Drugs Product

Table 129. Y-mAbs Therapeutics Revenue in Radionuclide-conjugated Drugs Business (US$ Million), 2021–2026

Table 130. Y-mAbs Therapeutics Recent Development

Table 131. Fusion Pharmaceuticals Company Details

Table 132. Fusion Pharmaceuticals Business Overview

Table 133. Fusion Pharmaceuticals Radionuclide-conjugated Drugs Product

Table 134. Fusion Pharmaceuticals Revenue in Radionuclide-conjugated Drugs Business (US$ Million), 2021–2026

Table 135. Fusion Pharmaceuticals Recent Development

Table 136. Research Programs/Design for This Report

Table 137. Key Data Information from Secondary Sources

Table 138. Key Data Information from Primary Sources

Table 139. Authors List of This Report

List of Figures

Figure 1. Radionuclide-conjugated Drugs Picture

Figure 2. Global Radionuclide-conjugated Drugs Market Size Comparison by Type (US$ Million), 2021–2032

Figure 3. Global Radionuclide-conjugated Drugs Market Share by Type: 2025 vs 2032

Figure 4. Beta-emitting Features

Figure 5. Targeted Alpha Therapy Features

Figure 6. Global Radionuclide-conjugated Drugs Market Size by Application (US$ Million), 2021–2032

Figure 7. Global Radionuclide-conjugated Drugs Market Share by Application: 2025 vs 2032

Figure 8. Solid Tumor Case Studies

Figure 9. Non Hodgkin Lymphoma Case Studies

Figure 10. Radionuclide-conjugated Drugs Report Years Considered

Figure 11. Global Radionuclide-conjugated Drugs Market Size (US$ Million), Year-over-Year: 2021–2032

Figure 12. Global Radionuclide-conjugated Drugs Market Size, (US$ Million), 2021 vs 2025 vs 2032

Figure 13. Global Radionuclide-conjugated Drugs Market Share by Region: 2025 vs 2032

Figure 14. Global Radionuclide-conjugated Drugs Market Share by Players in 2025

Figure 15. Global Radionuclide-conjugated Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

Figure 16. The Top 10 and 5 Players Market Share by Radionuclide-conjugated Drugs Revenue in 2025

Figure 17. North America Radionuclide-conjugated Drugs Market Size YoY Growth (US$ Million), 2021–2032

Figure 18. North America Radionuclide-conjugated Drugs Market Share by Country (2021–2032)

Figure 19. United States Radionuclide-conjugated Drugs Market Size YoY Growth (US$ Million), 2021–2032

Figure 20. Canada Radionuclide-conjugated Drugs Market Size YoY Growth (US$ Million), 2021–2032

Figure 21. Europe Radionuclide-conjugated Drugs Market Size YoY Growth (US$ Million), 2021–2032

Figure 22. Europe Radionuclide-conjugated Drugs Market Share by Country (2021–2032)

Figure 23. Germany Radionuclide-conjugated Drugs Market Size YoY Growth (US$ Million), 2021–2032

Figure 24. France Radionuclide-conjugated Drugs Market Size YoY Growth (US$ Million), 2021–2032

Figure 25. U.K. Radionuclide-conjugated Drugs Market Size YoY Growth (US$ Million), 2021–2032

Figure 26. Italy Radionuclide-conjugated Drugs Market Size YoY Growth (US$ Million), 2021–2032

Figure 27. Russia Radionuclide-conjugated Drugs Market Size YoY Growth (US$ Million), 2021–2032

Figure 28. Ireland Radionuclide-conjugated Drugs Market Size YoY Growth (US$ Million), 2021–2032

Figure 29. Asia-Pacific Radionuclide-conjugated Drugs Market Size YoY Growth (US$ Million), 2021–2032

Figure 30. Asia-Pacific Radionuclide-conjugated Drugs Market Share by Region (2021–2032)

Figure 31. China Radionuclide-conjugated Drugs Market Size YoY Growth (US$ Million), 2021–2032

Figure 32. Japan Radionuclide-conjugated Drugs Market Size YoY Growth (US$ Million), 2021–2032

Figure 33. South Korea Radionuclide-conjugated Drugs Market Size YoY Growth (US$ Million), 2021–2032

Figure 34. Southeast Asia Radionuclide-conjugated Drugs Market Size YoY Growth (US$ Million), 2021–2032

Figure 35. India Radionuclide-conjugated Drugs Market Size YoY Growth (US$ Million), 2021–2032

Figure 36. Australia & New Zealand Radionuclide-conjugated Drugs Market Size YoY Growth (US$ Million), 2021–2032

Figure 37. Latin America Radionuclide-conjugated Drugs Market Size YoY Growth (US$ Million), 2021–2032

Figure 38. Latin America Radionuclide-conjugated Drugs Market Share by Country (2021–2032)

Figure 39. Mexico Radionuclide-conjugated Drugs Market Size YoY Growth (US$ Million), 2021–2032

Figure 40. Brazil Radionuclide-conjugated Drugs Market Size YoY Growth (US$ Million), 2021–2032

Figure 41. Middle East & Africa Radionuclide-conjugated Drugs Market Size YoY Growth (US$ Million), 2021–2032

Figure 42. Middle East & Africa Radionuclide-conjugated Drugs Market Share by Country (2021–2032)

Figure 43. Israel Radionuclide-conjugated Drugs Market Size YoY Growth (US$ Million), 2021–2032

Figure 44. Saudi Arabia Radionuclide-conjugated Drugs Market Size YoY Growth (US$ Million), 2021–2032

Figure 45. UAE Radionuclide-conjugated Drugs Market Size YoY Growth (US$ Million), 2021–2032

Figure 46. Bayer Revenue Growth Rate in Radionuclide-conjugated Drugs Business (2021–2026)

Figure 47. Novartis Revenue Growth Rate in Radionuclide-conjugated Drugs Business (2021–2026)

Figure 48. Lantheus Revenue Growth Rate in Radionuclide-conjugated Drugs Business (2021–2026)

Figure 49. Aurobindo Pharma Revenue Growth Rate in Radionuclide-conjugated Drugs Business (2021–2026)

Figure 50. Mundipharma Revenue Growth Rate in Radionuclide-conjugated Drugs Business (2021–2026)

Figure 51. China Isotope & Radiation Revenue Growth Rate in Radionuclide-conjugated Drugs Business (2021–2026)

Figure 52. Curium Pharmaceuticals Revenue Growth Rate in Radionuclide-conjugated Drugs Business (2021–2026)

Figure 53. Gilead Sciences Revenue Growth Rate in Radionuclide-conjugated Drugs Business (2021–2026)

Figure 54. Clarity Pharmaceuticals Revenue Growth Rate in Radionuclide-conjugated Drugs Business (2021–2026)

Figure 55. Curasight Revenue Growth Rate in Radionuclide-conjugated Drugs Business (2021–2026)

Figure 56. Nordic Nanovector Revenue Growth Rate in Radionuclide-conjugated Drugs Business (2021–2026)

Figure 57. Philogen Revenue Growth Rate in Radionuclide-conjugated Drugs Business (2021–2026)

Figure 58. RadioMedix Revenue Growth Rate in Radionuclide-conjugated Drugs Business (2021–2026)

Figure 59. Telix Pharmaceuticals Revenue Growth Rate in Radionuclide-conjugated Drugs Business (2021–2026)

Figure 60. Orano Med Revenue Growth Rate in Radionuclide-conjugated Drugs Business (2021–2026)

Figure 61. Actinium Pharmaceuticals Revenue Growth Rate in Radionuclide-conjugated Drugs Business (2021–2026)

Figure 62. Y-mAbs Therapeutics Revenue Growth Rate in Radionuclide-conjugated Drugs Business (2021–2026)

Figure 63. Fusion Pharmaceuticals Revenue Growth Rate in Radionuclide-conjugated Drugs Business (2021–2026)

Figure 64. Bottom-up and Top-down Approaches for This Report

Figure 65. Data Triangulation

Figure 66. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic

$2900

Single User License

Multi User

Electronic

$4350

Multi User License

Enterprise License

Electronic

$5800

Enterprise License

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions